levodopa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dopamine receptor agonists, dopamine derivatives, used as antiparkinsonism/prolactin inhibitors 1567 59-92-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • levodopa
  • ledopa
  • 3-Hydroxy-L-tyrosine
  • DOPA
  • dihydroxyphenylalanine
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
  • Molecular weight: 197.19
  • Formula: C9H11NO4
  • CLOGP: -2.82
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 103.78
  • ALOGS: -1.78
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3.50 g O
0.60 g O
0.45 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 66 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 674.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 41 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 23 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.76 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 19, 2019 EMA Acorda Therapeutics Ireland Limited
June 4, 1970 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 439.40 15.40 184 12673 31818 63444347
Hallucination 249.79 15.40 149 12708 54668 63421497
On and off phenomenon 220.34 15.40 55 12802 1780 63474385
Muscle rigidity 187.94 15.40 75 12782 11425 63464740
Hallucination, visual 177.85 15.40 84 12773 19214 63456951
Parkinson's disease 168.93 15.40 41 12816 1178 63474987
Impulse-control disorder 159.19 15.40 36 12821 754 63475411
Freezing phenomenon 142.14 15.40 36 12821 1236 63474929
Bradykinesia 132.77 15.40 47 12810 5141 63471024
Tremor 123.86 15.40 143 12714 132096 63344069
Neuroleptic malignant syndrome 118.86 15.40 55 12802 12001 63464164
Delirium 109.65 15.40 87 12770 50454 63425711
Compulsive shopping 102.47 15.40 25 12832 734 63475431
Delusion 94.67 15.40 47 12810 11970 63464195
Pleurothotonus 92.75 15.40 26 12831 1323 63474842
Parkinsonism 82.74 15.40 41 12816 10398 63465767
Dopamine dysregulation syndrome 81.40 15.40 16 12841 164 63476001
Stereotypy 77.57 15.40 18 12839 424 63475741
Stoma site discharge 75.41 15.40 23 12834 1575 63474590
Dementia 72.51 15.40 46 12811 18748 63457417
Sudden onset of sleep 68.51 15.40 17 12840 536 63475629
Fall 67.48 15.40 203 12654 392131 63084034
Dystonia 66.60 15.40 39 12818 13780 63462385
Stoma site erythema 63.36 15.40 19 12838 1228 63474937
Gambling disorder 63.28 15.40 19 12838 1233 63474932
Akinesia 62.88 15.40 20 12837 1573 63474592
Fibroma 61.52 15.40 17 12840 820 63475345
Abnormal behaviour 60.02 15.40 43 12814 21383 63454782
Speech disorder 57.80 15.40 55 12802 40574 63435591
Torticollis 55.02 15.40 19 12838 1930 63474235
Hyperkinesia 53.54 15.40 18 12839 1686 63474479
Myoclonus 51.83 15.40 35 12822 15833 63460332
Product residue present 51.58 15.40 22 12835 3957 63472208
Gait disturbance 51.32 15.40 114 12743 183064 63293101
Dropped head syndrome 51.31 15.40 11 12846 178 63475987
Stoma site reaction 48.03 15.40 11 12846 244 63475921
Orthostatic hypotension 47.77 15.40 47 12810 36113 63440052
Therapeutic product effect variable 46.81 15.40 15 12842 1208 63474957
Joint swelling 46.08 15.40 6 12851 327660 63148505
Camptocormia 45.93 15.40 11 12846 298 63475867
Drug interaction 45.52 15.40 125 12732 229006 63247159
Rash 45.27 15.40 29 12828 560842 62915323
Confusional state 44.05 15.40 126 12731 236254 63239911
Stoma site irritation 43.74 15.40 10 12847 220 63475945
Product complaint 43.63 15.40 29 12828 12780 63463385
Reduced facial expression 43.51 15.40 16 12841 1950 63474215
Alopecia 43.33 15.40 8 12849 337528 63138637
Psychotic disorder 42.78 15.40 38 12819 25674 63450491
Ileus 42.27 15.40 30 12827 14695 63461470
Agitation 41.97 15.40 56 12801 59701 63416464
Jealous delusion 40.34 15.40 7 12850 33 63476132
Restlessness 38.37 15.40 38 12819 29415 63446750
Disorientation 37.41 15.40 43 12814 39409 63436756
Posture abnormal 37.36 15.40 15 12842 2317 63473848
Vascular encephalopathy 37.28 15.40 10 12847 431 63475734
Peripheral swelling 37.06 15.40 5 12852 265937 63210228
Dysphagia 36.71 15.40 65 12792 88520 63387645
Movement disorder 36.01 15.40 32 12825 21629 63454536
Hypersexuality 35.61 15.40 10 12847 512 63475653
Aortic valve incompetence 34.51 15.40 19 12838 5969 63470196
Somnolence 33.99 15.40 96 12761 178589 63297576
Deep brain stimulation 33.51 15.40 6 12851 35 63476130
Drug withdrawal syndrome 33.43 15.40 34 12823 27160 63449005
Stoma site pain 33.04 15.40 11 12846 999 63475166
Choking 32.76 15.40 22 12835 9857 63466308
Nasopharyngitis 32.67 15.40 6 12851 254251 63221914
Device difficult to use 32.03 15.40 24 12833 12772 63463393
Aggression 31.88 15.40 31 12826 23467 63452698
Eczema eyelids 30.66 15.40 7 12850 153 63476012
Tarsal tunnel syndrome 30.26 15.40 9 12848 565 63475600
Hypokinesia 30.21 15.40 24 12833 13912 63462253
Pruritus 30.07 15.40 18 12839 361435 63114730
Device issue 29.72 15.40 30 12827 23751 63452414
Headache 29.53 15.40 52 12805 633189 62842976
Ketonuria 29.12 15.40 9 12848 644 63475521
Swelling 28.66 15.40 10 12847 275368 63200797
Paranoia 27.24 15.40 21 12836 11658 63464507
Pain 26.89 15.40 70 12787 740558 62735607
Heat stroke 26.81 15.40 9 12848 839 63475326
Tension 26.74 15.40 13 12844 3162 63473003
Abdominal discomfort 26.65 15.40 16 12841 320869 63155296
Oromandibular dystonia 26.65 15.40 8 12849 519 63475646
Hypersensitivity 26.63 15.40 13 12844 292672 63183493
Cerebral atrophy 26.27 15.40 15 12842 5051 63471114
Wrong product administered 26.13 15.40 16 12841 6125 63470040
Purpura senile 26.12 15.40 8 12849 555 63475610
Device use issue 25.92 15.40 12 12845 2618 63473547
Glossodynia 25.79 15.40 3 12854 178873 63297292
Parkinsonism hyperpyrexia syndrome 25.63 15.40 6 12851 147 63476018
Hepatic enzyme increased 25.51 15.40 5 12852 202323 63273842
Hallucination, auditory 25.50 15.40 21 12836 12803 63463362
Arthropathy 25.35 15.40 8 12849 234784 63241381
Anxiety 25.33 15.40 99 12758 217442 63258723
Blood creatine phosphokinase increased 25.27 15.40 31 12826 30399 63445766
Rheumatoid arthritis 25.10 15.40 10 12847 253809 63222356
Drug hypersensitivity 25.10 15.40 16 12841 310671 63165494
Coma 25.09 15.40 46 12811 64318 63411847
Psychomotor hyperactivity 24.49 15.40 19 12838 10644 63465521
Diarrhoea 24.18 15.40 70 12787 715296 62760869
Depressed level of consciousness 23.73 15.40 44 12813 62034 63414131
Resorption bone increased 23.23 15.40 9 12848 1265 63474900
Resting tremor 23.14 15.40 8 12849 815 63475350
Delusion of parasitosis 22.54 15.40 4 12853 22 63476143
Vestibular disorder 22.22 15.40 9 12848 1422 63474743
Cognitive disorder 21.89 15.40 40 12817 55775 63420390
Exposure during pregnancy 21.48 15.40 3 12854 155544 63320621
Retroperitoneal fibrosis 21.44 15.40 6 12851 303 63475862
Product use issue 21.29 15.40 9 12848 220511 63255654
Infection 21.11 15.40 10 12847 229163 63247002
Therapeutic response shortened 20.63 15.40 18 12839 11870 63464295
Orthostatic intolerance 20.22 15.40 8 12849 1189 63474976
Application site reaction 19.97 15.40 7 12850 743 63475422
Labelled drug-disease interaction issue 19.85 15.40 4 12853 47 63476118
Cogwheel rigidity 19.45 15.40 9 12848 1961 63474204
Treatment failure 19.41 15.40 8 12849 199035 63277130
Off label use 19.30 15.40 71 12786 674391 62801774
Coronary artery dissection 19.02 15.40 7 12850 855 63475310
Product administration error 18.89 15.40 23 12834 22374 63453791
Progressive supranuclear palsy 18.82 15.40 4 12853 62 63476103
Device occlusion 18.81 15.40 14 12843 7373 63468792
Balance disorder 18.69 15.40 48 12809 84374 63391791
Cross sensitivity reaction 18.65 15.40 9 12848 2153 63474012
Wound 18.65 15.40 5 12852 163258 63312907
Hypophagia 18.51 15.40 27 12830 31232 63444933
Abnormal dreams 18.40 15.40 16 12841 10500 63465665
Parkinsonian gait 18.37 15.40 6 12851 513 63475652
Fatigue 18.02 15.40 106 12751 887922 62588243
Tongue necrosis 17.69 15.40 3 12854 12 63476153
Nasal mucosal discolouration 17.69 15.40 3 12854 12 63476153
Withdrawal syndrome 17.63 15.40 21 12836 19976 63456189
Completed suicide 17.53 15.40 4 12853 145669 63330496
Yawning 17.48 15.40 7 12850 1073 63475092
Urticaria 17.27 15.40 6 12851 165796 63310369
Bradyphrenia 17.26 15.40 13 12844 6967 63469198
Lower respiratory tract infection 17.25 15.40 3 12854 132304 63343861
Ammonia increased 16.97 15.40 11 12846 4645 63471520
Nuchal rigidity 16.88 15.40 6 12851 663 63475502
Stoma site hypergranulation 16.76 15.40 5 12852 317 63475848
Drug intolerance 16.57 15.40 23 12834 308638 63167527
Pneumonia aspiration 16.48 15.40 27 12830 34513 63441652
Stomatitis 16.32 15.40 4 12853 138721 63337444
Dysarthria 15.98 15.40 30 12827 42681 63433484
Serotonin syndrome 15.87 15.40 24 12833 28658 63447507
Erysipelas 15.83 15.40 13 12844 7892 63468273
Obsessive-compulsive disorder 15.81 15.40 10 12847 4050 63472115
Kleptomania 15.71 15.40 3 12854 26 63476139
Loss of consciousness 15.60 15.40 56 12801 118065 63358100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 428.88 15.06 197 13283 22216 34921235
Gambling disorder 361.03 15.06 91 13389 1569 34941882
On and off phenomenon 310.58 15.06 88 13392 2409 34941042
Hypersexuality 286.13 15.06 74 13406 1419 34942032
Hallucination 271.45 15.06 195 13285 51303 34892148
Dopamine dysregulation syndrome 267.05 15.06 56 13424 400 34943051
Impulse-control disorder 232.48 15.06 61 13419 1240 34942211
Parkinson's disease 203.65 15.06 56 13424 1368 34942083
Muscle rigidity 202.67 15.06 93 13387 10425 34933026
Hallucination, visual 156.57 15.06 93 13387 17698 34925753
Neuroleptic malignant syndrome 130.39 15.06 83 13397 17851 34925600
Fall 126.90 15.06 256 13224 202629 34740822
Bradykinesia 123.38 15.06 49 13431 3844 34939607
Akinesia 123.10 15.06 42 13438 2142 34941309
Freezing phenomenon 120.77 15.06 38 13442 1498 34941953
Tremor 92.23 15.06 135 13345 82452 34860999
Gambling 85.16 15.06 19 13461 187 34943264
Dementia 81.41 15.06 56 13424 13692 34929759
Delusion 78.46 15.06 53 13427 12582 34930869
Sudden onset of sleep 77.47 15.06 20 13460 380 34943071
Orthostatic hypotension 72.51 15.06 68 13412 25851 34917600
Abnormal behaviour 70.79 15.06 66 13414 24903 34918548
Confusional state 70.55 15.06 165 13315 143995 34799456
Parkinsonism 70.14 15.06 42 13438 8096 34935355
Psychotic disorder 70.03 15.06 65 13415 24387 34919064
Gait disturbance 67.35 15.06 119 13361 85021 34858430
Dysphagia 65.33 15.06 99 13381 62282 34881169
Therapeutic product effect variable 61.10 15.06 26 13454 2430 34941021
Delirium 59.64 15.06 79 13401 43912 34899539
Obsessive-compulsive disorder 59.37 15.06 33 13447 5531 34937920
Compulsive shopping 58.28 15.06 16 13464 388 34943063
Jealous delusion 57.47 15.06 15 13465 298 34943153
Dystonia 54.55 15.06 40 13440 10805 34932646
Paraphilia 53.41 15.06 11 13469 71 34943380
Agitation 53.01 15.06 86 13394 57313 34886138
Stoma site discharge 51.86 15.06 19 13461 1194 34942257
Saliva discolouration 50.35 15.06 9 13471 23 34943428
Reduced facial expression 50.04 15.06 18 13462 1073 34942378
Aggression 49.80 15.06 68 13412 38896 34904555
Diarrhoea 47.94 15.06 48 13432 389864 34553587
Hyperkinesia 44.92 15.06 19 13461 1749 34941702
Somnolence 43.58 15.06 117 13363 110999 34832452
Binge eating 43.24 15.06 10 13470 117 34943334
Stoma site erythema 42.64 15.06 15 13465 838 34942613
Device use issue 42.49 15.06 14 13466 640 34942811
Off label use 41.66 15.06 61 13419 419463 34523988
Fibroma 40.77 15.06 12 13468 376 34943075
Postural reflex impairment 38.74 15.06 6 13474 3 34943448
Febrile neutropenia 38.54 15.06 4 13476 136845 34806606
Embedded device 38.15 15.06 11 13469 320 34943131
Restlessness 38.02 15.06 48 13432 25434 34918017
Phlebitis infective 37.77 15.06 9 13471 121 34943330
Cognitive disorder 36.54 15.06 50 13430 28643 34914808
Product cleaning inadequate 36.09 15.06 6 13474 8 34943443
Posture abnormal 34.54 15.06 17 13463 2222 34941229
Mobility decreased 33.19 15.06 49 13431 30079 34913372
Persecutory delusion 32.26 15.06 17 13463 2563 34940888
Compulsions 32.22 15.06 9 13471 233 34943218
Therapeutic response shortened 32.12 15.06 25 13455 7379 34936072
Impulsive behaviour 32.11 15.06 16 13464 2146 34941305
Marital problem 32.04 15.06 7 13473 62 34943389
Compulsive sexual behaviour 31.89 15.06 9 13471 242 34943209
Libido increased 31.52 15.06 12 13468 839 34942612
Obsessive-compulsive personality disorder 31.08 15.06 8 13472 150 34943301
Pleurothotonus 30.78 15.06 13 13467 1192 34942259
Abnormal dreams 29.48 15.06 24 13456 7554 34935897
Hypertonia 29.23 15.06 19 13461 4227 34939224
Stereotypy 29.20 15.06 11 13469 747 34942704
Speech disorder 28.62 15.06 42 13438 25644 34917807
Pneumonia aspiration 27.37 15.06 54 13426 41849 34901602
Apathy 27.06 15.06 22 13458 6910 34936541
Motor dysfunction 26.94 15.06 22 13458 6952 34936499
Device dislocation 26.89 15.06 21 13459 6228 34937223
Deep brain stimulation 26.68 15.06 5 13475 18 34943433
Tension 26.25 15.06 14 13466 2161 34941290
Camptocormia 25.89 15.06 7 13473 160 34943291
Product residue present 25.83 15.06 15 13465 2731 34940720
Aortic valve incompetence 25.75 15.06 20 13460 5884 34937567
Stoma site irritation 25.33 15.06 7 13473 174 34943277
Device difficult to use 25.08 15.06 15 13465 2882 34940569
Balance disorder 24.89 15.06 51 13429 40603 34902848
Device issue 24.21 15.06 24 13456 9753 34933698
Platelet count decreased 24.20 15.06 8 13472 119709 34823742
Autonomic nervous system imbalance 24.17 15.06 14 13466 2537 34940914
Product complaint 23.64 15.06 19 13461 5871 34937580
Disorientation 23.17 15.06 44 13436 33144 34910307
Pruritus 23.12 15.06 13 13467 141968 34801483
Movement disorder 23.09 15.06 26 13454 12222 34931229
Hyperthermia 22.63 15.06 24 13456 10553 34932898
Depression 22.21 15.06 85 13395 97013 34846438
Wrong technique in device usage process 21.90 15.06 11 13469 1501 34941950
Sleep attacks 21.83 15.06 6 13474 146 34943305
Parkinsonian gait 21.60 15.06 8 13472 518 34942933
Illusion 21.38 15.06 9 13471 818 34942633
Neutropenia 20.72 15.06 18 13462 156760 34786691
Supine hypertension 20.60 15.06 7 13473 352 34943099
Product packaging difficult to open 20.58 15.06 3 13477 0 34943451
Extrapyramidal disorder 20.38 15.06 25 13455 12855 34930596
Device occlusion 19.90 15.06 18 13462 6527 34936924
Choking 19.75 15.06 16 13464 4999 34938452
Anxiety 19.52 15.06 83 13397 99345 34844106
Malignant neoplasm progression 19.41 15.06 5 13475 88041 34855410
Syncope 19.25 15.06 78 13402 91373 34852078
Mesenteric artery thrombosis 19.07 15.06 7 13473 442 34943009
Drug withdrawal syndrome 18.67 15.06 30 13450 19804 34923647
Dependence 18.54 15.06 9 13471 1141 34942310
Listless 18.41 15.06 10 13470 1602 34941849
Stoma site inflammation 18.33 15.06 7 13473 494 34942957
Pancytopenia 18.13 15.06 7 13473 95150 34848301
Formication 17.80 15.06 10 13470 1709 34941742
Economic problem 17.45 15.06 9 13471 1298 34942153
Psychomotor hyperactivity 17.41 15.06 20 13460 9602 34933849
Memory impairment 17.33 15.06 46 13434 43272 34900179
Micrographia 17.29 15.06 3 13477 6 34943445
Progressive supranuclear palsy 17.13 15.06 4 13476 49 34943402
Paranoia 16.84 15.06 22 13458 12046 34931405
Arthralgia 16.53 15.06 25 13455 170016 34773435
Hyperreflexia 16.51 15.06 12 13468 3194 34940257
Clonus 15.80 15.06 11 13469 2739 34940712
Chorea 15.67 15.06 8 13472 1129 34942322
Torticollis 15.56 15.06 8 13472 1146 34942305
Obsessive thoughts 15.55 15.06 7 13473 748 34942703
Acute kidney injury 15.39 15.06 63 13417 304925 34638526
Blood creatine phosphokinase increased 15.35 15.06 45 13435 44812 34898639
Drug hypersensitivity 15.21 15.06 6 13474 80523 34862928
Sleep disorder 15.14 15.06 36 13444 31652 34911799
Condition aggravated 15.08 15.06 126 13354 192070 34751381

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 645.48 14.36 284 19794 44489 79679821
On and off phenomenon 386.76 14.36 101 19977 3139 79721171
Hallucination 385.22 14.36 250 19828 85495 79638815
Dopamine dysregulation syndrome 326.70 14.36 63 20015 454 79723856
Impulse-control disorder 325.29 14.36 78 20000 1696 79722614
Muscle rigidity 305.34 14.36 132 19946 19750 79704560
Gambling disorder 289.98 14.36 73 20005 1953 79722357
Hallucination, visual 282.40 14.36 146 19932 32583 79691727
Hypersexuality 272.90 14.36 67 20011 1613 79722697
Parkinson's disease 268.19 14.36 66 20012 1605 79722705
Neuroleptic malignant syndrome 249.50 14.36 127 19951 27432 79696878
Bradykinesia 205.31 14.36 77 20001 7966 79716344
Akinesia 172.12 14.36 54 20024 3258 79721052
Tremor 144.01 14.36 195 19883 169888 79554422
Delusion 142.11 14.36 79 19999 20344 79703966
Parkinsonism 137.31 14.36 72 20006 16512 79707798
Freezing phenomenon 137.28 14.36 40 20038 1874 79722436
Dementia 128.28 14.36 79 19999 24580 79699730
Fall 127.21 14.36 337 19741 487292 79237018
Compulsive shopping 124.74 14.36 31 20047 785 79723525
Pleurothotonus 118.25 14.36 38 20040 2478 79721832
Dystonia 117.57 14.36 71 20007 21328 79702982
Delirium 115.96 14.36 124 19954 84503 79639807
Abnormal behaviour 106.95 14.36 82 19996 36339 79687971
Therapeutic product effect variable 97.11 14.36 31 20047 1978 79722332
Agitation 96.21 14.36 122 19956 99593 79624717
Orthostatic hypotension 94.58 14.36 92 19986 56072 79668238
Confusional state 88.08 14.36 225 19853 317772 79406538
Reduced facial expression 83.62 14.36 30 20048 2735 79721575
Sudden onset of sleep 81.31 14.36 21 20057 623 79723687
Hyperkinesia 80.24 14.36 29 20049 2700 79721610
Gait disturbance 78.47 14.36 166 19912 207340 79516970
Psychotic disorder 77.66 14.36 72 20006 41330 79682980
Torticollis 76.35 14.36 27 20051 2360 79721950
Gambling 75.16 14.36 17 20061 283 79724027
Stereotypy 73.34 14.36 21 20057 924 79723386
Aggression 70.35 14.36 75 20003 50883 79673427
Jealous delusion 68.26 14.36 16 20062 314 79723996
Camptocormia 66.94 14.36 17 20061 471 79723839
Dysphagia 64.99 14.36 113 19965 122023 79602287
Speech disorder 64.57 14.36 74 20004 54371 79669939
Aortic valve incompetence 61.23 14.36 35 20043 9495 79714815
Diarrhoea 60.65 14.36 80 19998 880409 78843901
Drug withdrawal syndrome 58.67 14.36 57 20021 34661 79689649
Posture abnormal 57.13 14.36 25 20053 3841 79720469
Stoma site discharge 55.82 14.36 21 20057 2188 79722122
Restlessness 54.80 14.36 63 20015 46429 79677881
Somnolence 53.98 14.36 157 19921 238824 79485486
Therapeutic response shortened 53.90 14.36 39 20039 15824 79708486
Paraphilia 53.87 14.36 10 20068 57 79724253
Deep brain stimulation 53.29 14.36 10 20068 61 79724249
Binge eating 51.84 14.36 14 20064 495 79723815
Persecutory delusion 48.44 14.36 24 20054 4885 79719425
Obsessive-compulsive disorder 46.97 14.36 25 20053 5902 79718408
Drug interaction 45.61 14.36 216 19862 414967 79309343
Device use issue 44.41 14.36 19 20059 2765 79721545
Postural reflex impairment 44.40 14.36 7 20071 11 79724299
Fibroma 44.04 14.36 14 20064 881 79723429
Product residue present 43.14 14.36 20 20058 3516 79720794
Blood creatine phosphokinase increased 43.03 14.36 67 20011 66023 79658287
Joint swelling 42.94 14.36 10 20068 288636 79435674
Disorientation 42.78 14.36 65 20013 62711 79661599
Pneumonia aspiration 42.36 14.36 67 20011 66900 79657410
Off label use 41.42 14.36 106 19972 907109 78817201
Pruritus 41.41 14.36 24 20054 394624 79329686
Peripheral swelling 40.79 14.36 9 20069 269608 79454702
Ileus 38.70 14.36 40 20038 26171 79698139
Febrile neutropenia 38.60 14.36 6 20072 230993 79493317
Sinusitis 37.88 14.36 3 20075 195498 79528812
Impulsive behaviour 37.25 14.36 17 20061 2883 79721427
Product complaint 36.87 14.36 29 20049 13320 79710990
Rash 36.30 14.36 56 20022 578302 79146008
Pain 36.28 14.36 77 20001 703725 79020585
Cognitive disorder 36.26 14.36 64 20014 69862 79654448
Progressive supranuclear palsy 36.15 14.36 8 20070 120 79724190
Parkinsonism hyperpyrexia syndrome 35.80 14.36 9 20069 239 79724071
Movement disorder 35.65 14.36 39 20039 27220 79697090
Apathy 35.43 14.36 28 20050 12949 79711361
Stoma site erythema 34.84 14.36 14 20064 1739 79722571
Cerebral atrophy 34.84 14.36 23 20055 8052 79716258
Drug hypersensitivity 34.58 14.36 16 20062 298900 79425410
Myoclonus 33.47 14.36 38 20040 27622 79696688
Dropped head syndrome 32.93 14.36 9 20069 333 79723977
Tricuspid valve incompetence 32.62 14.36 32 20046 19680 79704630
Alopecia 32.50 14.36 9 20069 231346 79492964
Headache 32.46 14.36 73 20005 653699 79070611
Autonomic nervous system imbalance 32.44 14.36 18 20060 4612 79719698
Hypertonia 32.18 14.36 21 20057 7211 79717099
Vascular encephalopathy 31.71 14.36 10 20068 613 79723697
Abdominal discomfort 31.27 14.36 12 20066 250715 79473595
Serotonin syndrome 31.21 14.36 47 20031 44980 79679330
Paranoia 31.14 14.36 31 20047 19401 79704909
Product cleaning inadequate 30.95 14.36 5 20073 10 79724300
Urticaria 30.51 14.36 5 20073 185196 79539114
Stoma site pain 30.22 14.36 12 20066 1446 79722864
Oromandibular dystonia 30.20 14.36 11 20067 1047 79723263
Anxiety 29.98 14.36 133 19945 248379 79475931
Stoma site irritation 29.90 14.36 8 20070 273 79724037
Resting tremor 29.72 14.36 12 20066 1509 79722801
Rheumatoid arthritis 29.49 14.36 8 20070 208462 79515848
Contraindicated product administered 28.95 14.36 3 20075 157535 79566775
Tarsal tunnel syndrome 28.94 14.36 9 20069 527 79723783
Fatigue 28.50 14.36 129 19949 929598 78794712
Hypokinesia 27.98 14.36 29 20049 19031 79705279
Eczema eyelids 27.91 14.36 7 20071 184 79724126
Mitral valve incompetence 27.59 14.36 35 20043 28530 79695780
Hyperthermia 27.49 14.36 28 20050 18009 79706301
Nasopharyngitis 27.24 14.36 15 20063 253866 79470444
Stoma site reaction 26.95 14.36 8 20070 400 79723910
Compulsions 26.95 14.36 8 20070 400 79723910
Withdrawal syndrome 26.09 14.36 33 20045 26821 79697489
Hepatic enzyme increased 25.84 14.36 7 20071 182603 79541707
Extrapyramidal disorder 25.49 14.36 30 20048 22649 79701661
Psychomotor hyperactivity 25.39 14.36 26 20052 16823 79707487
Obsessive-compulsive personality disorder 25.08 14.36 6 20072 129 79724181
Drug intolerance 25.04 14.36 18 20060 264101 79460209
Purpura senile 24.88 14.36 8 20070 522 79723788
Motor dysfunction 24.53 14.36 24 20054 14709 79709601
Parkinsonian gait 23.91 14.36 9 20069 939 79723371
Arthralgia 23.63 14.36 70 20008 571733 79152577
Swelling 22.96 14.36 13 20065 216698 79507612
Retroperitoneal fibrosis 22.78 14.36 8 20070 685 79723625
Hyperreflexia 22.69 14.36 18 20060 8367 79715943
Choking 22.59 14.36 21 20057 12080 79712230
Supine hypertension 22.39 14.36 7 20071 417 79723893
Syncope 22.36 14.36 97 19981 179352 79544958
Depressed level of consciousness 22.26 14.36 64 20014 96588 79627722
Hypersensitivity 22.19 14.36 20 20058 262219 79462091
Delusion of parasitosis 22.16 14.36 4 20074 19 79724291
Marital problem 22.06 14.36 6 20072 218 79724092
Mania 21.94 14.36 25 20053 18235 79706075
Ketonuria 21.79 14.36 9 20069 1199 79723111
Abnormal dreams 21.69 14.36 20 20058 11392 79712918
Saliva discolouration 21.53 14.36 5 20073 94 79724216
Aortic valve sclerosis 21.50 14.36 10 20068 1770 79722540
Chorea 21.45 14.36 11 20067 2406 79721904
Kleptomania 21.23 14.36 4 20074 25 79724285
Dementia with Lewy bodies 21.22 14.36 8 20070 838 79723472
Arthropathy 21.22 14.36 9 20069 177102 79547208
Infection 20.98 14.36 18 20060 241694 79482616
Dysarthria 20.92 14.36 50 20028 67572 79656738
Device difficult to use 20.80 14.36 21 20057 13364 79710946
Orthostatic intolerance 20.76 14.36 10 20068 1914 79722396
Pancytopenia 20.55 14.36 8 20070 165737 79558573
Balance disorder 20.43 14.36 63 20015 98794 79625516
Tension 20.11 14.36 13 20065 4391 79719919
Stomatitis 20.07 14.36 6 20072 146751 79577559
Resorption bone increased 20.06 14.36 9 20069 1466 79722844
Device issue 19.79 14.36 29 20049 27079 79697231
Granulocytopenia 19.74 14.36 19 20059 11412 79712898
Mesenteric artery thrombosis 19.54 14.36 7 20071 635 79723675
Intentional product use issue 19.43 14.36 7 20071 152105 79572205
Product packaging difficult to open 19.06 14.36 4 20074 46 79724264
Stoma site inflammation 18.99 14.36 7 20071 689 79723621
Product use issue 18.98 14.36 15 20063 209807 79514503
Labelled drug-disease interaction issue 18.98 14.36 4 20074 47 79724263
Cogwheel rigidity 18.93 14.36 11 20067 3077 79721233
Delusion of replacement 18.88 14.36 5 20073 164 79724146
Heat stroke 18.83 14.36 9 20069 1694 79722616
Platelet count decreased 18.79 14.36 13 20065 194651 79529659
Illusion 18.64 14.36 9 20069 1732 79722578
Formication 18.56 14.36 13 20065 5010 79719300
Sleep attacks 18.43 14.36 5 20073 180 79724130
Lower respiratory tract infection 18.19 14.36 5 20073 129215 79595095
Electrocardiogram J wave 18.07 14.36 4 20074 60 79724250
Femoral neck fracture 18.01 14.36 17 20061 9967 79714343
Hallucination, auditory 17.88 14.36 24 20054 20669 79703641
Asthma 17.62 14.36 6 20072 135089 79589221
Dermatillomania 17.57 14.36 5 20073 215 79724095
Yawning 17.52 14.36 8 20070 1358 79722952
Medical device site scab 17.47 14.36 3 20075 10 79724300
Libido increased 17.45 14.36 9 20069 1992 79722318
Treatment failure 16.97 14.36 11 20067 170475 79553835
Pyrexia 16.90 14.36 101 19977 678608 79045702
Pericarditis 16.75 14.36 3 20075 104233 79620077
Listless 16.66 14.36 11 20067 3850 79720460
Oral discomfort 16.44 14.36 16 20062 9744 79714566
Device dislocation 16.44 14.36 26 20052 25944 79698366
Malignant neoplasm progression 16.15 14.36 7 20071 135983 79588327
Exposure during pregnancy 16.06 14.36 3 20075 101129 79623181
Mitral valve disease 16.00 14.36 10 20068 3187 79721123
Mobility decreased 15.95 14.36 67 20011 122108 79602202
Ballismus 15.94 14.36 5 20073 301 79724009
Hypomania 15.87 14.36 14 20064 7530 79716780
Nuchal rigidity 15.86 14.36 7 20071 1097 79723213
Product physical issue 15.86 14.36 11 20067 4174 79720136
Vestibular disorder 15.73 14.36 9 20069 2446 79721864
Obsessive thoughts 15.69 14.36 7 20071 1125 79723185
Incoherent 15.63 14.36 14 20064 7678 79716632
Coronary artery dissection 15.62 14.36 7 20071 1137 79723173
Device occlusion 15.55 14.36 17 20061 11849 79712461
Wound 15.43 14.36 5 20073 116174 79608136
Dyspnoea 15.36 14.36 140 19938 856885 78867425
Gallbladder necrosis 15.08 14.36 4 20074 132 79724178
Subileus 15.01 14.36 12 20066 5642 79718668
Sudden death 14.89 14.36 23 20055 22488 79701822
Soft tissue mass 14.83 14.36 7 20071 1281 79723029
Cross sensitivity reaction 14.64 14.36 10 20068 3702 79720608
Gait inability 14.53 14.36 40 20038 58877 79665433
Urinary retention 14.52 14.36 39 20039 56591 79667719

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BA01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopa and dopa derivatives
ATC N04BA02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopa and dopa derivatives
ATC N04BA03 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopa and dopa derivatives
FDA CS M0003647 Catecholamines
FDA CS M0370111 Amino Acids, Aromatic
FDA EPC N0000175570 Catecholamine
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D020011 Protective Agents
MeSH PA D013566 Sympathomimetics
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
FDA EPC N0000193220 Aromatic Amino Acid
CHEBI has role CHEBI:35219 plant growth inhibitors
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48560 dopaminergic agents
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:59174 haptens
CHEBI has role CHEBI:62215 allelochemicals
CHEBI has role CHEBI:66956 antidyskinetic agent
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:76924 plant metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:35522 beta-adrenergic agonists
CHEBI has role CHEBI:35524 sympathomimetic
CHEBI has role CHEBI:38147 cardiotonic drugs
CHEBI has role CHEBI:76971 Escherichia coli metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002
Parkinson's disease indication 49049000 DOID:14330
Restless legs off-label use 32914008 DOID:0050425
Age-related macular degeneration off-label use 267718000 DOID:10871
Suicidal thoughts contraindication 6471006
Hallucinations contraindication 7011001
Dyskinesia contraindication 9748009
Peptic ulcer contraindication 13200003 DOID:750
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Orthostatic hypotension contraindication 28651003
Obstruction of bile duct contraindication 30144000
Depressive disorder contraindication 35489007
Conduction disorder of the heart contraindication 44808001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Diarrhea contraindication 62315008
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Psychoneurotic personality disorder contraindication 268634009
Malignant melanoma contraindication 372244006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.31 acidic
pKa2 9.07 acidic
pKa3 13.05 acidic
pKa4 10.01 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
42MG INBRIJA ACORDA N209184 Dec. 21, 2018 RX POWDER INHALATION 8404276 March 19, 2023 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
42MG INBRIJA ACORDA N209184 Dec. 21, 2018 RX POWDER INHALATION 8586093 March 19, 2023 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
23.75MG;95MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
36.25MG;145MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
48.75MG;195MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8377474 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8454998 Dec. 26, 2028 TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 8557283 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9089607 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9463246 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9533046 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
61.25MG;245MG RYTARY IMPAX LABS INC N203312 Jan. 7, 2015 RX CAPSULE, EXTENDED RELEASE ORAL 9901640 Dec. 26, 2028 TREATMENT OF PARKINSONS DISEASE
42MG INBRIJA ACORDA N209184 Dec. 21, 2018 RX POWDER INHALATION RE43711 Feb. 3, 2029 INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSONS DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11033521 March 28, 2039 METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11033521 March 28, 2039 METHOD OF TREATING PARKINSONS DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA—25 MG/LEVODOPA—100 MG, EACH SEGMENT HAVING CARBIDOPA—6.25 MG/LEVODOPA—25 MG
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11033521 March 28, 2039 TREATMENT OF PARKINSONS DISEASE
25MG;100MG DHIVY AVION PHARMS N214869 Nov. 12, 2021 RX TABLET ORAL 11439613 March 28, 2039 TREATMENT OF PARKINSONS DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(1A) dopamine receptor GPCR AGONIST WOMBAT-PK SCIENTIFIC LITERATURE
D(2) dopamine receptor GPCR AGONIST WOMBAT-PK SCIENTIFIC LITERATURE
Tyrosine-protein kinase Lck Kinase IC50 5.43 DRUG MATRIX
Large neutral amino acids transporter small subunit 1 Transporter IC50 4 CHEMBL
Tyrosine-protein kinase Fyn Kinase IC50 5.67 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.54 DRUG MATRIX
Arachidonate 15-lipoxygenase Enzyme IC50 5.65 DRUG MATRIX

External reference:

IDSource
4017790 VUID
N0000146151 NUI
D00059 KEGG_DRUG
4017790 VANDF
4019733 VANDF
C0023570 UMLSCUI
CHEBI:15765 CHEBI
CHEBI:18243 CHEBI
TY3 PDB_CHEM_ID
LDP PDB_CHEM_ID
CHEMBL1009 ChEMBL_ID
DB01235 DRUGBANK_ID
D007980 MESH_DESCRIPTOR_UI
6047 PUBCHEM_CID
2651 INN_ID
3639 IUPHAR_LIGAND_ID
46627O600J UNII
3628 RXNORM
1804 MMSL
4971 MMSL
6641 MMSL
d00216 MMSL
d00277 MMSL
001639 NDDF
004721 NDDF
15383004 SNOMEDCT_US
387086006 SNOMEDCT_US
412383006 SNOMEDCT_US
59187003 SNOMEDCT_US
65955006 SNOMEDCT_US
D004295 MESH_DESCRIPTOR_UI
C0013030 UMLSCUI
DB00988 DRUGBANK_ID
2417 INN_ID
D004298 MESH_DESCRIPTOR_UI
681 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SINEMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-3915 TABLET 100 mg ORAL NDA 25 sections
SINEMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-3916 TABLET 100 mg ORAL NDA 25 sections
SINEMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-3917 TABLET 250 mg ORAL NDA 25 sections
SINEMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-6722 TABLET 100 mg ORAL NDA 25 sections
SINEMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-6723 TABLET 250 mg ORAL NDA 25 sections
SINEMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-6724 TABLET 100 mg ORAL NDA 25 sections
Duopa HUMAN PRESCRIPTION DRUG LABEL 2 0074-3012 SUSPENSION 20 mg ENTERAL NDA 31 sections
Duopa HUMAN PRESCRIPTION DRUG LABEL 2 0074-3012 SUSPENSION 20 mg ENTERAL NDA 31 sections
Duopa HUMAN PRESCRIPTION DRUG LABEL 2 0074-3012 SUSPENSION 20 mg ENTERAL NDA 31 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0407 TABLET, FILM COATED 50 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0408 TABLET, FILM COATED 100 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0409 TABLET, FILM COATED 150 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0527 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0544 TABLET, FILM COATED 75 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0545 TABLET, FILM COATED 125 mg ORAL NDA 25 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9701 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9701 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9702 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0093-9702 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0228-2538 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0228-2538 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0228-2539 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0228-2539 TABLET 100 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0228-2540 TABLET 250 mg ORAL ANDA 11 sections
Carbidopa and levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0228-2540 TABLET 250 mg ORAL ANDA 11 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0078 TABLET 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0078 TABLET 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0085 TABLET 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0085 TABLET 100 mg ORAL ANDA 24 sections
Carbidopa and Levodopa HUMAN PRESCRIPTION DRUG LABEL 2 0378-0088 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 24 sections